Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation

Autor: Gregory Joseph, Petra Rocic, Ian Hunter, Rebecca Hutcheson, Michal L. Schwartzman, Rachana Maniyar, John R. Falck, Frank Zhang, Brenda Hutcheson, Katherine H. Gotlinger, Spencer D. Proctor, Chastity Bradford, Sachindra R. Joshi, Jenny Yang, Amanda Soler, Sachin A. Gupte
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
medicine.medical_specialty
Systolic hypertension
Blood Pressure
030204 cardiovascular system & hematology
Article
Collagen Type I
Losartan
Microcirculation
Rats
Sprague-Dawley
03 medical and health sciences
0302 clinical medicine
Vascular Stiffness
Diastole
Internal medicine
Matrix Metalloproteinase 12
Hydroxyeicosatetraenoic Acids
medicine
Animals
Cytochrome P450 Family 4
RNA
Small Interfering
Molecular Biology
Metabolic Syndrome
biology
business.industry
medicine.disease
Angiotensin II
Elastin
Compliance (physiology)
Enzyme Activation
030104 developmental biology
Blood pressure
Endocrinology
Collagen Type III
Hypertension
Proteolysis
cardiovascular system
Arterial stiffness
biology.protein
Metabolic syndrome
Cytochrome P-450 CYP4A
Cardiology and Cardiovascular Medicine
business
Compliance
Zdroj: Journal of molecular and cellular cardiology. 117
ISSN: 1095-8584
Popis: Arterial stiffness plays a causal role in development of systolic hypertension. 20-hydroxyeicosatetraeonic acid (20-HETE), a cytochrome P450 (CYP450)-derived arachidonic acid metabolite, is known to be elevated in resistance arteries in hypertensive animal models and loosely associated with obesity in humans. However, the role of 20-HETE in the regulation of large artery remodeling in metabolic syndrome has not been investigated. We hypothesized that elevated 20-HETE in metabolic syndrome increases matrix metalloproteinase 12 (MMP12) activation leading to increased degradation of elastin, increased large artery stiffness and increased systolic blood pressure. 20-HETE production was increased ~7 fold in large, conduit arteries of metabolic syndrome (JCR:LA-cp, JCR) vs. normal Sprague-Dawley (SD) rats. This correlated with increased elastin degradation (~7 fold) and decreased arterial compliance (~75% JCR vs. SD). 20-HETE antagonists blocked elastin degradation in JCR rats concomitant with blocking MMP12 activation. 20-HETE antagonists normalized, and MMP12 inhibition (pharmacological and MMP12-shRNA-Lnv) significantly improved (~50% vs. untreated JCR) large artery compliance in JCR rats. 20-HETE antagonists also decreased systolic (182 ± 3 mmHg JCR, 145 ± 3 mmHg JCR + 20-HETE antagonists) but not diastolic blood pressure in JCR rats. Whereas diastolic pressure was fully angiotensin II (Ang II)-dependent, systolic pressure was only partially Ang II-dependent, and large artery stiffness was Ang II-independent. Thus, 20-HETE-dependent regulation of systolic blood pressure may be a unique feature of metabolic syndrome related to high 20-HETE production in large, conduit arteries, which results in increased large artery stiffness and systolic blood pressure. These findings may have implications for management of systolic hypertension in patients with metabolic syndrome.
Databáze: OpenAIRE
Externí odkaz: